LOXL2 and breast cancer: Similarly, it has been shown recently that in breast cancer the pro-metastatic function of LOXL2 is independent of its role for ECM remodelling, since neither Loxl2 ablation nor overexpression affected ECM stiffness or organisation in the metastatic and primary tumour sites [35].